F9 and hemophilia B: Detection a naturally occurring gain-of-function (Padua) mutation in humans was a significant breakthrough in gene therapy for hemophilia B. The IX-R338L mutation, characterized by replacing arginine with leucine at position 338 in the catalytic domain of factor IX, results in increased activity (Nathwani 2022).